Eumovate

How to order Eumovate

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Eumovate on Prescriptsy

Eumovate is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Eumovate is a topical corticosteroid cream and ointment containing clobetasone butyrate 0.05%, used to treat a range of inflammatory skin conditions including eczema (atopic dermatitis), contact dermatitis, insect bite reactions, and mild to moderate psoriasis.

Manufactured by GlaxoSmithKline (GSK), Eumovate is one of the most widely used moderately potent topical steroids in the United Kingdom.

It is available as a pharmacy medicine (P) in a 15 g tube for short-term use without a prescription, while larger pack sizes and prolonged treatment courses require a prescription from a GP or authorised prescriber.

Inflammatory skin conditions are extremely common in the UK. Eczema alone affects approximately 1 in 5 children and 1 in 10 adults, according to the National Eczema Society.

These conditions cause redness, itching, swelling, dryness, and scaling, which can significantly impair quality of life, disrupt sleep, and affect psychological wellbeing.

Topical corticosteroids have been the mainstay of anti-inflammatory treatment for skin conditions since the 1950s and remain the most effective first-line therapy for eczema flares and dermatitis.

This page provides a comprehensive clinical guide to Eumovate for patients in the United Kingdom, covering how it works, how to use it correctly, the potency ladder, when it is appropriate, potential side effects, important warnings, emollient use, and how to obtain it from the NHS or a pharmacy.

Important safety information about Eumovate

Before reading further, note the following essential safety points.

• Eumovate should not be used on untreated skin infections (bacterial, fungal, or viral), including cold sores, impetigo, and ringworm.
• Do not use on acne, rosacea, or perioral dermatitis.
• Limit use on the face to 5 days or less unless directed by a prescriber.
• Do not use for more than 7 days without medical advice when purchased over the counter.
• Always use emollients alongside topical corticosteroids for optimal skin care.

Understanding topical corticosteroid potency

Topical corticosteroids are classified into four potency groups in the UK, following the BNF classification system. Understanding where Eumovate sits on this ladder is important for safe and effective use.

• Mild: hydrocortisone 0.5% to 1% (available over the counter)
• Moderate: clobetasone butyrate 0.05% (Eumovate), alclometasone dipropionate 0.05%
• Potent: betamethasone valerate 0.1% (Betnovate), mometasone furoate 0.1% (Elocon)
• Very potent: clobetasol propionate 0.05% (Dermovate)

Eumovate occupies the moderate tier, making it more effective than over-the-counter hydrocortisone for stubborn or moderately severe inflammation, while carrying a lower risk of side effects than potent or very potent preparations.

This balance of efficacy and safety makes it particularly useful as a step-up treatment when hydrocortisone is insufficient, or as a step-down from a potent steroid when a flare is coming under control.

How Eumovate works: mechanism of action

Clobetasone butyrate belongs to the glucocorticoid class of anti-inflammatory agents. When applied to inflamed skin, it penetrates the epidermis and dermis and binds to intracellular glucocorticoid receptors.

The activated receptor complex translocates to the cell nucleus, where it modifies gene transcription.

Specifically, it upregulates anti-inflammatory proteins (such as lipocortin-1, which inhibits phospholipase A2) and downregulates pro-inflammatory mediators including prostaglandins, leukotrienes, cytokines (interleukins, tumour necrosis factor), and chemokines.

The net effect is a reduction in the cardinal signs of inflammation: redness, swelling, heat, itching, and scaling.

Clobetasone butyrate is designed to be metabolised relatively quickly in the skin, which limits the amount of active drug that reaches the systemic circulation.

This local metabolism is one of the reasons that moderately potent topical steroids like Eumovate have a better safety profile than more potent agents when used as directed.

Conditions treated by Eumovate

Eczema (atopic dermatitis)

Eczema is a chronic relapsing condition characterised by dry, itchy, inflamed skin.

NICE guideline CG57 recommends a stepped approach to management, starting with regular emollients and escalating to topical corticosteroids of appropriate potency for flare management.

Eumovate is suitable for moderate eczema flares on the body and limbs, and for short-term use on thinner-skinned areas such as the face, neck, and flexures where potent steroids would be inappropriate.

Contact dermatitis

Contact dermatitis occurs when the skin reacts to direct contact with an irritant (irritant contact dermatitis) or allergen (allergic contact dermatitis).

Common triggers include detergents, soaps, metals (nickel), fragrances, and preservatives. Treatment involves identifying and avoiding the trigger, using emollients, and applying a topical corticosteroid to control inflammation.

Eumovate is appropriate for moderate contact dermatitis affecting limited body areas.

Insect bite reactions

Insect bites and stings can cause localised inflammatory reactions with redness, swelling, and intense itching.

While most reactions are self-limiting, persistent or exaggerated reactions may benefit from a short course of a moderately potent topical corticosteroid such as Eumovate to reduce inflammation and discomfort.

Mild to moderate psoriasis

Psoriasis is an immune-mediated condition causing thickened, scaly, red plaques on the skin.

Topical corticosteroids are commonly used for limited plaque psoriasis, often in combination with vitamin D analogues.

Eumovate may be appropriate for thin plaques or for use on sensitive areas, though more severe or widespread psoriasis typically requires potent topical steroids or specialist treatment.

How to apply Eumovate correctly

Correct application technique is essential for effective treatment and minimising side effects. Wash and dry your hands before and after application (unless treating the hands themselves).

Apply a thin layer of Eumovate to the affected area only, gently rubbing it in until absorbed. Do not apply to unaffected skin.

The fingertip unit system

The fingertip unit (FTU) is a practical guide developed to help patients apply the right amount of topical steroid.

One FTU is the strip of cream or ointment squeezed from a standard tube nozzle along an adult's index finger from the tip to the first crease.

This is approximately 0.5 grams and covers an area of skin equivalent to two adult flat palms (including fingers).

The recommended FTU quantities for different body areas in adults are approximately: face and neck, 2.5 FTUs; one hand (both sides), 1 FTU; one arm, 3 FTUs; one leg, 6 FTUs; trunk (front), 7 FTUs; trunk (back including buttocks), 7 FTUs.

Children require proportionally smaller amounts based on their body size.

Using emollients alongside Eumovate

Emollients (moisturisers) are the foundation of treatment for eczema and dry skin conditions.

They restore the skin barrier, reduce water loss, and decrease the severity and frequency of flares.

Emollients should be applied liberally and frequently, ideally at least twice daily and after bathing, regardless of whether a flare is present.

When using both an emollient and Eumovate, apply the emollient first and wait at least 15 to 30 minutes before applying the corticosteroid.

This prevents dilution of the steroid and allows each preparation to be absorbed effectively.

NICE recommends that emollients should be prescribed in large quantities (250 g to 500 g per week for adults with widespread eczema).

Treatment duration and stepping down

Topical corticosteroids should be used for the shortest duration necessary to control symptoms. For over-the-counter Eumovate, the maximum recommended duration without medical advice is 7 days.

When prescribed, courses of up to 4 weeks may be appropriate, with review thereafter.

Once the flare is controlled (reduced redness, itching, and scaling), gradually reduce the frequency of application (for example, from twice daily to once daily, then to every other day) before stopping.

This helps prevent rebound flares that can occur with abrupt discontinuation after prolonged use.

For patients with frequently relapsing eczema, a proactive (maintenance) approach may be recommended by a dermatologist.

This involves applying a topical corticosteroid to previously affected areas twice weekly (weekend therapy) alongside daily emollient use, to reduce the frequency and severity of flares.

Side effects of Eumovate

Local side effects

When used correctly at the recommended dose and duration, Eumovate is well tolerated. Mild burning or stinging at the application site may occur transiently.

Prolonged use, application under occlusive dressings, or use on thin-skinned areas (face, axillae, groin) may increase the risk of local side effects including skin thinning (atrophy), stretch marks (striae), visible small blood vessels (telangiectasia), increased hair growth (hypertrichosis), changes in skin colour (hypo- or hyperpigmentation), and acneiform eruptions.

These effects are generally reversible if the preparation is discontinued early, but striae may be permanent.

Systemic effects

Systemic absorption is very low with moderately potent topical corticosteroids used at standard doses on limited areas.

However, prolonged use on large body surface areas, under occlusion, or in children (who have a higher surface area to body weight ratio) can lead to sufficient systemic absorption to cause hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome features (moon face, weight gain, skin fragility), or growth retardation in children.

These are extremely rare with Eumovate at recommended doses.

Contact allergy

Rarely, patients may develop allergic contact dermatitis to the corticosteroid itself or to excipients in the formulation (such as preservatives or emulsifiers).

This should be suspected if the treated area worsens rather than improves. Patch testing can identify the responsible allergen.

When to seek medical advice about side effects

Contact your GP or pharmacist if your skin condition worsens, if new symptoms develop (spreading redness, pustules, crusting suggesting infection), or if you notice skin thinning, stretch marks, or persistent discolouration.

Report adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Skin infections

Do not apply Eumovate to skin with untreated bacterial infections (impetigo, cellulitis), fungal infections (ringworm, athlete's foot, candida), or viral infections (cold sores, chickenpox, shingles).

Corticosteroids suppress the local immune response and may mask the signs of infection while allowing it to spread.

If infection is present, it must be treated with an appropriate antimicrobial agent.

In some cases, a combined corticosteroid-antimicrobial preparation may be appropriate, but this should be directed by a prescriber.

Conditions worsened by topical corticosteroids

Eumovate should not be used on acne vulgaris, rosacea, perioral dermatitis, or nappy rash. These conditions are exacerbated by topical corticosteroids. If you are unsure of your diagnosis, consult a pharmacist or GP before using any topical steroid.

Use in children

Children should be treated under medical supervision. Their thinner skin and higher body surface area to weight ratio increase the risk of systemic absorption.

Use the minimum effective amount for the shortest duration. The over-the-counter pack is licensed for children aged 12 years and over; use in younger children requires a prescription.

Pregnancy and breastfeeding

Eumovate may be used during pregnancy and breastfeeding when considered necessary, at the lowest effective dose for the shortest time. Extensive or prolonged use should be avoided.

Do not apply to the breasts before breastfeeding. Discuss any concerns with your midwife, health visitor, or GP.

How to get Eumovate in the UK

Eumovate cream 15 g is available as a pharmacy medicine from any UK pharmacy without a prescription.

The pharmacist will ask about your symptoms to ensure the product is suitable.

For larger pack sizes, prolonged courses, or ointment formulation, a prescription is required from a GP or authorised online prescriber.

The NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Generic clobetasone butyrate 0.05% cream is also available and may be dispensed as an alternative to the branded product.

Caring for your skin long-term

Eczema and dermatitis are often chronic or relapsing conditions.

Long-term skin health depends on consistent use of emollients, avoidance of known triggers (soaps, detergents, certain fabrics, allergens), and prompt treatment of flares with an appropriate topical corticosteroid.

Use soap substitutes and emollient bath additives. Wear soft cotton clothing against the skin. Keep the home environment at a comfortable temperature and humidity.

Manage stress, as it can trigger or worsen eczema. Your GP, practice nurse, or pharmacist can help develop a personalised skin care plan.

When to seek medical advice

Consult your GP or NHS 111 if your skin condition does not improve within 7 days of over-the-counter treatment, if it worsens, if it spreads to new areas, or if you develop signs of skin infection (increased redness, swelling, warmth, crusting, pus).

Seek emergency care (call 999 or attend A&E) if you develop a widespread skin reaction with blistering, or signs of a severe allergic reaction (swelling of the face or throat, difficulty breathing).

Report suspected adverse reactions to the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Eumovate Cream, Summary of Product Characteristics (EMC)
• Clobetasone butyrate, British National Formulary (BNF)
• NICE CG57: Atopic eczema in under 12s: diagnosis and management
• Atopic eczema, NHS
• MHRA Yellow Card Scheme